5439042026-08-265439042026-08-262026-08-26543904Mankind Pharma LimitedMANKINDNOTLISTEDINE634S01028NewOther Restructuringtrue2026-08-2616:05:002026-08-26Business of BSVL is proposed to be integrated with the Company by way of voluntary liquidation of BSVL. This would entail the following benefits: 1. Drive operational efficiency and effective utilization of resources which are currently carried out through two separate legal entities. This will enable consolidation of material business in the Company. 2. Improved organizational execution capability and therapy leadership arising from the pooling of human capital having diverse skills, talent, and vast experience. 3. Further efficiencies are expected to flow from improved cash management, reduced compliance requirements, enhanced governance and rationalization of expenses.Business of BSVL will be distributed to the Company (holding 96% shares in BSVL) on a going concern basis immediately upon receipt of necessary approvals and various documents, including licenses, permits, authorizations, consents, no-objection certificates, etc., in the name of the Company,. Appian, holding 4% shares in BSVL, shall receive cash proportionate to its shareholding i.e., an amount equivalent to 4% of the fair value of BSVL, as determined in accordance with the valuation report to be obtained from an independent valuer.Business of BSVL will be distributed to the Company (holding 96% shares in BSVL) on a going concern basis immediately upon receipt of necessary approvals and various documents, including licenses, permits, authorizations, consents, no-objection certificates, etc., in the name of the Company,. Appian, holding 4% shares in BSVL, shall receive cash proportionate to its shareholding i.e., an amount equivalent to 4% of the fair value of BSVL, as determined in accordance with the valuation report to be obtained from an independent valuer.false